# Efficacy and Safety of Masitinib Versus Placebo in the Treatment of ALS Patients

> **NCT03127267** · PHASE3 · RECRUITING · sponsor: **AB Science** · enrollment: 495 (estimated)

## Conditions studied

- Amyotrophic Lateral Sclerosis

## Interventions

- **DRUG:** Masitinib (6.0)
- **DRUG:** Riluzole
- **DRUG:** Placebo
- **DRUG:** Masitinib (4.5)

## Key facts

- **NCT ID:** NCT03127267
- **Lead sponsor:** AB Science
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2021-02-02
- **Primary completion:** 2027-12
- **Final completion:** 2027-12
- **Target enrollment:** 495 (ESTIMATED)
- **Last updated:** 2025-09-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03127267

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03127267, "Efficacy and Safety of Masitinib Versus Placebo in the Treatment of ALS Patients". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT03127267. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*